OP0018 The value of adding mri to a clinical treat-to-target strategy in rheumatoid arthritis patients in clinical remission: clinical and radiographic outcomes from the imagine-ra randomised controlled trial
| Autor: | Anne Grethe Jurik, Ole Rintek Madsen, Lykke Midtbøll Ørnbjerg, B Ejbjerg, Morten Ilum Boesen, Henning Bliddal, Daniel Glinatski, Mikkel Østergaard, Sabrina Mai Nielsen, Jan Alexander Villadsen, Kristian Stengaard-Pedersen, Marcin Ryszard Kowalski, Jakob M Møller, P. Bennet, Hanne Merete Lindegaard, A. H. Nielsen, Kim Hørslev-Petersen, Bente Jensen, Niels Steen Krogh, Lone Balding, Ellen Margrethe Hauge, Oliver Hendricks, Signe Møller-Bisgaard, Merete Lund Hetland, Torkell Ellingsen, Karsten Asmussen, Henrik S. Thomsen, René dePont Christensen |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
030203 arthritis & rheumatology
0301 basic medicine medicine.medical_specialty business.industry Radiography Treat to target Physical function medicine.disease law.invention 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Randomized controlled trial law Rheumatoid arthritis Joint damage medicine Clinical endpoint Radiology Osteitis business |
| Zdroj: | WEDNESDAY, 13 JUNE 2018. |
| DOI: | 10.1136/annrheumdis-2018-eular.1204 |
| Popis: | Background Targeting MRI remission in rheumatoid arthritis (RA) patients in clinical remission may improve clinical outcome and halt joint damage progression. Objectives To determine whether a treat-to-target (T2T) strategy based on structured MRI assessments targeting absence of osteitis/bone marrow oedema (BME) would lead to improved clinical and radiographic outcomes, compared with a conventional T2T strategy in RA patients in clinical remission. Methods The IMAGINE-RA study was a 2 year investigator-initiated, randomised, open-label multicentre study. Two hundred RA patients in clinical remission (defined as: DAS28-CRP Results Primary and secondary clinical and radiographic outcomes at 24 months are presented in the table 1. 76 patients in the MRI T2T arm and 95 patients in conventional T2T arm completed the study. Of them 64 patients (85%) in the MRI T2T arm and 83 patients (88%) in the conventional T2T arm reached the primary clinical endpoint (chi-square=0.324, p=0.569) and 49 patients (66%) in the MRI T2T arm and 58 (62%) in the conventional T2T arm reached the primary radiographic endpoint (chi-square=0.265, p=0.606). ACR/EULAR remission rates, swollen joint count, patient VAS global and HAQ favoured the MRI T2T arm (p Conclusions Targeting absence of MRI BME in addition to a conventional T2T strategy in RA patients in clinical remission had no effect on the probability of achieving DAS28-CRP remission or halt radiographic progression. However, more patients achieved ACR/EULAR remission and improvements in physical function when MRI was used for treatment guidance. Clinicaltrials.gov Identifier: NCT01656278 Disclosure of Interest None declared |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|